Additionally, tail vein-infused GMR-AML1 cells in NSG mice engrafted in the mice, resulting in AML growth and mortality of all mice in 4 to 5 weeks post engraftment (vide infra, Fig. 2E). Here, RUNX1 is linked to acute myeloid leukemia.